A new study has found that young individuals suffering from extremity soft tissue sarcoma are less likely to receive radiation and more likely to undergo chemotherapy when compared with older individuals. The study was reported in “JAMA Network Open.”
Extremity soft tissues sarcomas are a rare group of tumors that commonly occur in an individual’s extremities.
For their research, the scientists carried out a retrospective study that included more than 8,900 patients and compared the utilization of definitive treatment from 2004 to 2014. The cohorts from the National Cancer Database comprised of about 3,750 patients aged 65 and above, roughly 3,930 patients aged between 40 and 64, and 1,280 young individuals, aged between 18 and 39.
The scientists noted that in comparison with the older people, young patients were more likely to have differentiated tumor types and tumors that were smaller than five centimeters. In their report, the researchers stated that this discovery suggested that extremity soft tissue sarcoma wasn’t as aggressive in the younger population. However, they added, this was complicated by the fact that, unlike older adults, more young people had their limbs amputated.
Their findings show that while only 5.2% and 5.4% of individuals aged 65 and above and those aged between 40 and 64 respectively underwent amputation, more than 8% of young individuals underwent amputation. The researchers note that despite this disparity, the chances of undergoing amputation instead of limb-sparing surgery in a multivariable analysis weren’t substantially different across the cohorts.
The researchers also found that while only 9.2% of individuals aged 65 and above and 29.5% of people between 40 and 64 respectively received chemotherapy, more than 39% of young adults received chemotherapy. In comparison with young people, the odds ratio for receiving chemotherapy was 0.16 for those aged 65 and older and 0.52 for individuals aged between 40 and 64.
In addition, the scientists also discovered that radiation was more commonly administered to individuals aged 65 and older and those aged between 40 and 64. In contrast to young people, the odd ratio for receiving radiation was 1.33 and 1.40 for those aged 65 and above and those aged between 40 and 64 respectively.
In their report, the scientists stated that positive surgical margins weren’t linked to the use of radiation. They highlighted that this was unique to young people. In their conclusion, the scientists noted that more research was needed to determine the clinical outcomes of these differences in practice.
In the meantime, companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) are seeking to develop better remedies for soft tissue sarcomas as well as many neuropsychiatric disorders affecting millions of people around the globe.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork.